Characterising the phenotypic evolution of circulating tumour cells during treatment

Simon Chang Hao Tsao, Jing Wang, Yuling Wang, Andreas Behren, Jonathan Cebon, Matt Trau

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Real-time monitoring of cancer cells’ phenotypic evolution during therapy can provide vital tumour biology information for treatment management. Circulating tumour cell (CTC) analysis has emerged as a useful monitoring tool, but its routine usage is restricted by either limited multiplexing capability or sensitivity. Here, we demonstrate the use of antibody-conjugated and Raman reporter-coated gold nanoparticles for simultaneous labelling and monitoring of multiple CTC surface markers (named as “cell signature”), without the need for isolating individual CTCs. We observe cell heterogeneity and phenotypic changes of melanoma cell lines during molecular targeted treatment. Furthermore, we follow the CTC signature changes of 10 stage-IV melanoma patients receiving immunological or molecular targeted therapies. Our technique maps the phenotypic evolution of patient CTCs sensitively and rapidly, and shows drug-resistant clones having different CTC signatures of potential clinical value. We believe our proposed method is of general interest in the CTC relevant research and translation fields.
LanguageEnglish
Article number1482
Pages1-10
Number of pages10
JournalNature Communications
Volume9
Issue number1
DOIs
Publication statusPublished - 16 Apr 2018
Externally publishedYes

Fingerprint

Circulating Neoplastic Cells
Tumors
tumors
Cells
signatures
Melanoma
Monitoring
therapy
Molecular Targeted Therapy
Therapeutics
Information Management
Gold
Nanoparticles
Neoplasms
cells
antibodies
multiplexing
Multiplexing
biology
cultured cells

Bibliographical note

Copyright The Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Cite this

Tsao, Simon Chang Hao ; Wang, Jing ; Wang, Yuling ; Behren, Andreas ; Cebon, Jonathan ; Trau, Matt. / Characterising the phenotypic evolution of circulating tumour cells during treatment. In: Nature Communications. 2018 ; Vol. 9, No. 1. pp. 1-10.
@article{bc7dc275163c406180e695c20d649f9d,
title = "Characterising the phenotypic evolution of circulating tumour cells during treatment",
abstract = "Real-time monitoring of cancer cells’ phenotypic evolution during therapy can provide vital tumour biology information for treatment management. Circulating tumour cell (CTC) analysis has emerged as a useful monitoring tool, but its routine usage is restricted by either limited multiplexing capability or sensitivity. Here, we demonstrate the use of antibody-conjugated and Raman reporter-coated gold nanoparticles for simultaneous labelling and monitoring of multiple CTC surface markers (named as “cell signature”), without the need for isolating individual CTCs. We observe cell heterogeneity and phenotypic changes of melanoma cell lines during molecular targeted treatment. Furthermore, we follow the CTC signature changes of 10 stage-IV melanoma patients receiving immunological or molecular targeted therapies. Our technique maps the phenotypic evolution of patient CTCs sensitively and rapidly, and shows drug-resistant clones having different CTC signatures of potential clinical value. We believe our proposed method is of general interest in the CTC relevant research and translation fields.",
author = "Tsao, {Simon Chang Hao} and Jing Wang and Yuling Wang and Andreas Behren and Jonathan Cebon and Matt Trau",
note = "Copyright The Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",
year = "2018",
month = "4",
day = "16",
doi = "10.1038/s41467-018-03725-8",
language = "English",
volume = "9",
pages = "1--10",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Springer, Springer Nature",
number = "1",

}

Characterising the phenotypic evolution of circulating tumour cells during treatment. / Tsao, Simon Chang Hao; Wang, Jing; Wang, Yuling; Behren, Andreas; Cebon, Jonathan; Trau, Matt.

In: Nature Communications, Vol. 9, No. 1, 1482, 16.04.2018, p. 1-10.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Characterising the phenotypic evolution of circulating tumour cells during treatment

AU - Tsao,Simon Chang Hao

AU - Wang,Jing

AU - Wang,Yuling

AU - Behren,Andreas

AU - Cebon,Jonathan

AU - Trau,Matt

N1 - Copyright The Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2018/4/16

Y1 - 2018/4/16

N2 - Real-time monitoring of cancer cells’ phenotypic evolution during therapy can provide vital tumour biology information for treatment management. Circulating tumour cell (CTC) analysis has emerged as a useful monitoring tool, but its routine usage is restricted by either limited multiplexing capability or sensitivity. Here, we demonstrate the use of antibody-conjugated and Raman reporter-coated gold nanoparticles for simultaneous labelling and monitoring of multiple CTC surface markers (named as “cell signature”), without the need for isolating individual CTCs. We observe cell heterogeneity and phenotypic changes of melanoma cell lines during molecular targeted treatment. Furthermore, we follow the CTC signature changes of 10 stage-IV melanoma patients receiving immunological or molecular targeted therapies. Our technique maps the phenotypic evolution of patient CTCs sensitively and rapidly, and shows drug-resistant clones having different CTC signatures of potential clinical value. We believe our proposed method is of general interest in the CTC relevant research and translation fields.

AB - Real-time monitoring of cancer cells’ phenotypic evolution during therapy can provide vital tumour biology information for treatment management. Circulating tumour cell (CTC) analysis has emerged as a useful monitoring tool, but its routine usage is restricted by either limited multiplexing capability or sensitivity. Here, we demonstrate the use of antibody-conjugated and Raman reporter-coated gold nanoparticles for simultaneous labelling and monitoring of multiple CTC surface markers (named as “cell signature”), without the need for isolating individual CTCs. We observe cell heterogeneity and phenotypic changes of melanoma cell lines during molecular targeted treatment. Furthermore, we follow the CTC signature changes of 10 stage-IV melanoma patients receiving immunological or molecular targeted therapies. Our technique maps the phenotypic evolution of patient CTCs sensitively and rapidly, and shows drug-resistant clones having different CTC signatures of potential clinical value. We believe our proposed method is of general interest in the CTC relevant research and translation fields.

UR - http://purl.org/au-research/grants/arc/DE140101056

UR - http://www.scopus.com/inward/record.url?scp=85045583786&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-03725-8

DO - 10.1038/s41467-018-03725-8

M3 - Article

VL - 9

SP - 1

EP - 10

JO - Nature Communications

T2 - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 1482

ER -